文献速递围术期管理与 ERAS胃肠外科

代谢与减重手术在系统性红斑狼疮患者中的长期安全性与疾病修饰潜力

Long-term safety and disease-modifying potential of metabolic and bariatric surgery in patients with systemic lupus erythematosus.
PubMed 文献 · Surg Endosc · 2026-03-30

本研究基于TriNetX多中心回顾性队列(2009–2024年,140余家机构),比较SLE患者行MBS与非SLE行MBS者及未行MBS的SLE患者。SLE患者术后维生素D缺乏与低白蛋白血症风险更高,但死亡风险相当;MBS与SLE患者激素、免疫抑制剂及抗疟药使用减少、炎症指标下降、eGFR改善及死亡率降低相关,RYGB营养风险高于SG。

要点

  • SLE患者行MBS后维生素D缺乏和低白蛋白血症风险显著高于非SLE患者。
  • MBS与SLE患者激素、免疫抑制剂及抗疟药使用减少和炎症指标下降相关。
  • RYGB较SG与更高的溃疡、骨质疏松和低白蛋白血症发生率相关。

核心结论

  • MBS与SLE患者疾病控制改善、肾功能保护和死亡率降低相关,但营养风险增加,尤其在RYGB后。
  • 需仔细选择患者并长期多学科随访以优化这一复杂人群的结局。

研究设计与样本

  • 多中心回顾性队列研究,使用TriNetX全球联邦研究网络2009–2024年140余家医疗机构数据。
  • 纳入行SG或RYGB的SLE成人患者,并与倾向评分匹配的非SLE行MBS患者及未行MBS的SLE患者比较。
  • 共123219例MBS患者中713例(0.6%)患SLE,随访五年。

主要发现

  • 匹配后SLE患者维生素D缺乏发生率53.8% vs 45.1%(p=0.002),低白蛋白血症9.7% vs 4.7%(p=0.001),死亡率与非SLE患者相当。
  • SLE队列中RYGB较SG与更高的溃疡、骨质疏松和低白蛋白血症发生率相关。
  • 与匹配的未行MBS的SLE患者相比,MBS队列激素使用32.9% vs 47.5%、免疫抑制剂9.1% vs 22.0%、抗疟药11.2% vs 28.1%,CRP和ESR更低,eGFR改善,死亡率1.4% vs 4.4%(p=0.001)。

临床怎么用

  • SLE患者行MBS前应评估营养风险并加强围术期及长期营养监测。
  • RYGB后需特别关注溃疡、骨质疏松和低白蛋白血症风险。
  • MBS后多学科随访可能有助于减少免疫抑制药物使用并监测疾病活动。

局限性

  • 回顾性队列设计可能存在残余混杂。
  • SLE患者占MBS总人群比例较小(0.6%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity commonly coexists with systemic lupus erythematosus (SLE), exacerbating metabolic, cardiovascular, and renal complications. Metabolic and bariatric surgery (MBS) achieves durable weight loss and improves metabolic health, but its long-term safety and potential disease-modifying effects in SLE remain unclear. METHODS: A multicenter, retrospective cohort study was conducted using the TriNetX global federated research network, comprising data from over 140 healthcare organizations between 2009 and 2024. Adults with SLE who underwent sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) were compared with propensity score-matched cohorts of non-SLE patients undergoing MBS and patients with SLE who do not undergo MBS. Primary outcomes included long-term nutritional and metabolic safety. Secondary outcomes evaluated changes in immunosuppressive medication use, inflammatory markers, renal function, and mortality over a five-year follow-up. RESULTS: Among 123,219 MBS patients, 713 (0.6%) had SLE. After matching, patients with SLE had higher risks of vitamin D deficiency (53.8% vs 45.1%, p = 0.002) and hypoalbuminemia (9.7% vs 4.7%, p = 0.001), while mortality was comparable to patients without SLE. Within the SLE cohort, RYGB was associated with higher rates of ulcer, osteoporosis, and hypoalbuminemia compared with SG. Compared with matched patients with SLE who do not undergo MBS, MBS cohort was associated with reduced use of corticosteroids (32.9% vs 47.5%), immunosuppressants (9.1% vs 22.0%), and antimalarials (11.2% vs 28.1%), lower CRP and ESR levels, improved eGFR, and lower mortality (1.4% vs 4.4%, p = 0.001). CONCLUSIONS: In this large real-world study, MBS was associated with improved disease control, renal preservation, and reduced mortality in patients with SLE, though at the expense of greater nutritional risks-particularly after RYGB. Careful patient selection and long-term multidisciplinary follow-up are essential to optimize outcomes in this complex population.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Zhu X, Wang Q, Mocanu V, et al. Long-term safety and disease-modifying potential of metabolic and bariatric surgery in patients with systemic lupus erythematosus. Surg Endosc. 2026. PMID: 42377514. doi:10.1007/s00464-025-12557-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。